US$90 Billion by 2030: How Bayer, Mesoblast and NurExone Are

Based on an article by Vincent Uhr of Dr. Eva Reuter Investor Relations reviewed by Samuel Boltruczyk

Regenerative medicine has long since moved beyond the search for a single miracle therapy. The market covers cell therapies, gene therapies, tissue replacement, and novel biological delivery systems. Grand View Research puts the global market at roughly US$48.3 billion in 2026 and expects it to reach approximately US$90 billion by 2030. That would represent compound annual growth of 16.8 percent between 2025 and 2030.

Underneath those headline numbers sit very different technological approaches. Bayer aims to replace lost nerve cells with newly produced ones. Mesoblast treats patients with living stromal cells sourced from donors. NurExone, by contrast, is developing a cell-free approach that uses natural vesicles as delivery vehicles. The three approaches show that different answers are emerging to the same underlying question in the same future market: does regenerative medicine need to deliver new cells, or can the body's own repair mechanisms be activated by the right biological signals?

Bayer aims to replace dopamine neurons

Bayer AG (ISIN DE000BAY0017), through its subsidiary BlueRock Therapeutics, is taking a particularly direct approach. Its candidate, bemdaneprocel, is made up of precursor cells for dopamine-producing neurons. The cells are produced from pluripotent stem cells and surgically transplanted into the brains of Parkinson's patients, where they are intended to integrate and restore part of the lost dopamine function.

The first patient was dosed in a pivotal Phase III trial in September 2025. The trial is randomized and double-blind, with a sham surgical procedure as the comparator arm. According to BlueRock, earlier data from a small Phase I study of twelve participants showed no serious adverse events attributed to the cell product over 24 months, alongside encouraging trends on secondary endpoints. That is not yet a demonstration of efficacy, but it does show how far cell-based tissue replacement has already moved in clinical development.

Mesoblast brings living donor cells into standard of care

Mesoblast Limited (ISIN AU000000MSB8) has demonstrated with Ryoncil that a standardized donor-cell therapy can secure regulatory approval. The FDA approved the product in December 2024 for children aged two months and older with steroid-refractory acute graft-versus-host disease. Ryoncil consists of cultured mesenchymal stromal cells from the bone marrow of adult donors and is administered as an intravenous infusion.

The approval is an important piece of regulatory validation for industrially manufactured, off-the-shelf cell products. But it also highlights the operational complexity these therapies carry. Living cells have to be produced to a defined quality, shipped at cryogenic temperatures, and thawed under controlled conditions before use. Ryoncil's FDA documentation specifies storage at or below minus 135 degrees Celsius. The product is approved, but it depends on a highly specialized supply and administration chain.

NurExone separates the therapeutic signal from the living cell

NurExone Biologic Inc. (ISIN CA67059R1091) is pursuing a third architecture through its ExoTherapy platform. The company uses exosomes, which are nanoscale vesicles released by cells, as biological delivery vehicles. The vesicles are sourced from mesenchymal stem cells, loaded with a defined therapeutic cargo, and designed to carry that cargo into damaged tissue. The lead candidate, ExoPTEN, is in preclinical development for acute spinal cord injury and optic nerve injury.

The potential advantage is that no living cells need to be administered. A cell-free product could, over time, be easier to store, standardize, and deploy as an off-the-shelf therapy, while avoiding the risk of graft-versus-host disease associated with the transplantation of living donor immune cells. Post-production loading also creates a degree of modularity: in principle, the same biological carrier can be combined with different payloads for different applications. For now, however, these advantages remain a development proposition rather than a demonstrated outcome. Exosomes also require demanding processes for purification, characterization, loading, potency measurement, and batch control.

Three routes into the same future market

Bayer, Mesoblast, and NurExone are not direct competitors in the same indication. What they do embody are three of the central models of regenerative medicine: replacement of lost cells, treatment with living therapeutic cells, and cell-free transmission of regenerative signals. That distinction matters to investors and to the industry because each model carries its own opportunities, costs, and regulatory risks.

NurExone's opportunity lies in a platform that combines biological delivery capability with defined payload loading, without needing to transplant living cells. That could make the technology easier to deploy in acute-injury settings, provided manufacturing, shelf life, and dosing can all be reliably controlled. ExoPTEN, however, has not yet entered human clinical trials. The projected US$90 billion covers the entire regenerative medicine market and should not be equated with NurExone's addressable revenue. The number instead illustrates why several technological paths are being funded and tested in parallel, and why a cell-free approach could establish a place of its own in this growing field, provided the clinical data supports it.

Sources

• Grand View Research — Regenerative Medicine Market: [grandviewresearch.com/industry-analysis/regenerative-medicine-market](grandviewresearch.com/industry-analysis/regenerative-medicine-market)

• BlueRock Therapeutics — First Parkinson's patient treated in pivotal Phase III trial of bemdaneprocel: [bluerocktx.com](bluerocktx.com)

• FDA — Ryoncil prescribing information: [fda.gov/media/184605/download](fda.gov/media/184605/download)

• Ryoncil (Mesoblast): [ryoncilhcp.com](ryoncilhcp.com)

• NurExone — ExoTherapy platform: [nurexone.com/exotherapy](nurexone.com/exotherapy)

Disclaimer: This content has been paid for by NurExone Biologic Inc. Cashu Group was compensated by NurExone Biologic Inc. for the creation and distribution of this content. The author is not a registered investment advisor or medical professional. NurExone's products are in the preclinical stage and have not been tested in humans or approved by any regulatory authority. All financial figures, scientific claims, pipeline details, and company data referenced come from NurExone Biologic Inc.'s public disclosures, press releases, and SEDAR+ filings. Preclinical results referenced are from animal studies and do not guarantee similar outcomes in humans. Orphan Drug Designations referenced provide regulatory incentives including potential market exclusivity upon approval but do not guarantee clinical success, regulatory approval, or commercial viability. The Made Scientific memorandum of understanding referenced is a binding MOU, not a completed definitive agreement; if the parties do not execute a definitive agreement within six months of MOU execution, the MOU and its exclusivity obligations automatically terminate. The ExoLyra memorandum of understanding referenced is a binding MOU for a proposed distribution agreement; a definitive distribution agreement has not yet been signed. Private placements completed in June and August 2026 resulted in additional share issuance and dilution to existing shareholders. References to other companies in the spinal cord injury and exosome therapeutics pipelines (including NervGen Pharma Inc., Lineage Cell Therapeutics, Aegle Therapeutics, and Capricor Therapeutics) are descriptive of the competitive landscape and are not comparisons implying equivalent clinical or commercial outcomes for NurExone. References to prior work by team members at other companies are historical and are not an indication of future performance at NurExone Biologic. The ExoTop naïve exosome commercial business is at an early stage and no anticipated revenue level is guaranteed; commercial arrangements referenced (including the ExoLyra Mexico MOU) may not produce anticipated revenues on the timelines currently disclosed. Investing in preclinical biotech companies involves significant risk, including the possible loss of all capital invested. The majority of preclinical drug candidates never achieve regulatory